INTRODUCTION
============

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease characterized by inflammation of the synovium that leads to destruction of cartilage and bone \[[@R1]\]. Despite the significant progress in treatment strategies and new therapeutics for RA \[[@R2]\], significant limitations as well as side effects are found in their efficacy \[[@R3]\]. Thus, there is a great interest in studying new therapies.

*Equisetum giganteum*L., also known as "cavalinha", "cola de caballo" or "giant horsetail", is a native plant of Central and South America. Methods for the preparation of this species, mainly decoction and infusion, are widely used in traditional medicine as diuretic, hemostatic, urinary disorders, inflammatory conditions \[[@R4]-[@R7]\] and rheumatic diseases \[[@R8]\], among other applications. *E. giganteum* constitution includes flavonoids, styrylpyrones glycosides, hydroxycinnamic acid derivatives \[[@R9]\], metals, silica \[[@R10]\] and some apolar compounds in their oleoresin, as alkanes, fatty acids, methyl esters and steroid triterpenes \[[@R11]\].

Pharmacological studies revealed that the extracts of *E*. *giganteum* present antimicrobial effects \[[@R12]\], diuretic activity \[[@R4],[@R6]\] and no oral acute toxicity in mice \[[@R5]\]. Other *Equisetum* species have shown to present antioxidant, antinociceptive and anti-inflammatory activities \[[@R12],[@R13]\]. These data together with the experience in traditional uses indicate the possibility of employing *E*.*giganteum*for the treatment of inflammatory diseases.

Antigen-induced arthritis (AIA) is a T-cell dependent immunological model in mice. Similar to other *in vivo* model of arthritis, AIA shows mimics with human rheumatoid arthritis \[[@R14]\]. As a consequence, this animal model may represent an excellent *in vivo* model for preclinical testing of new potential therapies RA and other inflammatory diseases. The aim of this study was to evaluate the effect of aqueous extract of *E*.*giganteum* as an immunomodulatory therapy.

MATERIALS AND METHODOLOGY
=========================

Animals
-------

Male BALB/c wild-type mice (8-12 weeks, 20-25 g) were maintained in temperature-controlled rooms and were given water and food *ad libitum*. All experimental procedures involving animals were performed in accordance with the National Institutes of Health Guide for Care and Use of Animals and with the approval of our institutional ethics committee under number 120004.

Preparation of Aqueous Extract
------------------------------

The*E. giganteum*stems collected in May of 2011, in Santo Antônio da Patrulha, Rio Grande do Sul, Brazil (S 29° 52.374', W 50° 25.265', 12 m) were air-dried and grounded in a hammer mill. The plant authenticity was evaluated and the voucher specimen (number 88339) was deposited in the Herbarium at the Fundação Zoobotânica do Rio Grande do Sul (Porto Alegre, RS, Brazil). A decoction (plant: solvent ratio of 1:11.7, 95°C for 15 min) was prepared and filtered after cooled. The decoct was spray-dried using a Niro Production Minor atomizer (GEA, Copenhagen, Denmark).

The AEGH was prepared under decoction based on the traditional use of the plant and the good yield of the extraction process. Aqueous extractive solution obtained was then spray-dried. The resulting dried extract (AEGH) was used for the pharmacological tests. The chemical profile of the AEGH was not assessed in this study. However, the chemical and physicochemical profile of the plant has been previously established by our group \[[@R9]\], where we can verify high content of silica and minerals, as well as the presence of caffeic acid derivatives, ﬂavonoids and styrylpyrones.

Induction of AIA
----------------

AIA was induced according to *Grespan et al.* (2008) \[[@R16]\]. Fourteen BALB/c mice were sensitized by subcutaneous (s.c.) injected with 500 μg of mBSA (Sigma Aldrich, St. Louis/EUA) dissolved in 0.2 ml of an emulsion containing 0.1 ml of 0.9% saline and 0.1 ml of complete Freund's adjuvant (Sigma Aldrich, St. Louis/USA) administered on day 0. Booster injections were administered for almost 2 weeks (7-14 days) using incomplete Freund's adjuvant (Sigma Aldrich, St. Louis/USA). Treatment started at day 19 and mice received AEGH (600 mg/kg) or vehicle (0.9% saline) orally in 100 μl, twice a day. On day 21, arthritis was induced in pre-immunized animals by intra-articular (i.a.) injection with 30 μg of mBSA dissolved in 10 μl of saline into the left tibiofemoral joint. As a negative control 10 μl of saline without mBSA was injected into the right tibiofemoral joint (contralateral joint) of vehicle group, consisting in the saline group.

Evaluation of Articular Nociception
-----------------------------------

Articular nociception was evaluated on 0, 1, 3, 6 and 24 h after i.a. injection of mBSA according to *Oliveira et al.* (2011) \[[@R17]\]. Mice were placed in a quiet room in acrylic cages with a wire-grid floor for 15-30 minutes before testing for environmental adaptation. An electronic pressure meter was used, consisting of a hand-held force transducer fitted with a polypropylene tip (Insight Instruments, Ribeirão Preto, São Paulo/BR). An increasing perpendicular force was applied to the central area of the plantar surface of the hind paw to induce flexion of the tibiofemoral joint, followed by paw withdrawal. The electronic pressure meter automatically recorded the intensity of the force applied when the paw was withdrawn, with results expressed as the flexion-elicited withdrawal threshold in grams (g).

Evaluation of *In Vivo* Total Leucocytes Migration
--------------------------------------------------

After death, articular cavities of mice were washed twice with 5 μl phosphate buffered saline (0.15 M NaCL, 6.5 mM phosphate and 1 mM EDTA) in a final volume of 100 μl to evaluate leukocyte migration at 24 h after i.a. injection of mBSA. The total number of leukocytes was determined in a Neubauer chamber under optical microscopy.

Cell Viability Assay
--------------------

Cell viability was determined by MTT \[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H tetrazolium bromide\] assay \[[@R18]\]. Lymphocytes from non-sensitized BALB/c lymph nodes were removed aseptically and cultured in triplicate (5 X 10^5^ cells/well - 96-well plate) for 48 h at 37°C in 5% CO~2~ in RPMI medium, treated or not with AEGH (20, 40 and 80 μg/ml). Twenty microliters of MTT (0.5 mg/ml) was added in each well and after 4 h of incubation the supernatants were removed and 100 μl of DMSO (Sigma Aldrich, St. Louis/EUA) was added to dissolve the MTT formazan crystals. After shaking the plate, the absorbance of each well was read at 570 nm.

Lymphocyte Proliferation Assay
------------------------------

Lymphocyte proliferation assay was performed using MTT assay \[[@R18]\]. Lymph nodes of non-sensitized BALB/c were removed aseptically. Lymphocytes were extracted, plated and cultured in triplicate (5 X 10^5^ cells/well in a 96-well plate) for 48 h at 37°C in 5% CO~2~with RPMI medium stimulated with concanavalin A (ConA) (5 μg/ml) or lipopolysaccharide (LPS) (10 μg/ml) and treated or not with AEGH (80 μg/ml). Twenty microliters of MTT (0.5 mg/ml) was added in each well and after 4 h of incubation the supernatants were removed and 100 μl of DMSO (Sigma Aldrich, St. Louis/EUA) was added to dissolve the MTT formazan crystals. After shaking the plate, the absorbance of each well was read at 570 nm.

Statistical Analysis
--------------------

Data are presented as mean ± SEM. Groups were compared by the analysis of variance with Tukey's adjustment for multiple comparisons or by Student's t-test using GraphPad Prism 5.0. Statistical differences were considered to be significant when P \< 0.05.

RESULTS
=======

Treatment with AEGH Reduced Inflammatory Para-meters of Acute AIA
-----------------------------------------------------------------

In AIA model, mBSA injection into tibiofemoral joint of immunized mice induces inflammation which causes significant increased nociception and leukocyte migration into the articular cavity, as compared to the negative control contralateral joint in the same mice \[[@R17]\].

Nociception (Fig. **[1A](#F1){ref-type="fig"}**) was first noted 1 h after the antigenic challenge and became more intense in 3 h and 6 h, then remaining relatively stable till 24 h. Treatment with AEGH significantly reduced nociception on 3, 6 and 24 h (P \< 0.01).

Leukocyte infiltration triggered by i.a. injection plays an essential role in this experimental model and contributes to the articular damage \[[@R16]\], being an important marker of local inflammatory activity. Treatment with AEGH significantly reduced leukocyte recruitment (43.13%) to the site of inflammation (16.42 ± 6.54 x 10^4^leukocytes/cavity) as compared with vehicle (38.07 ± 4.24 x 10^4^leukocytes/cavity) (P \< 0.015) (Fig. **[1B](#F1){ref-type="fig"}**).

AEGH Inhibited *In Vitro* Lymphoproliferation
---------------------------------------------

Lymphocytes proliferation was induced with ConA, which present nonspecific action, stimulating both T and B lymphocytes, and with LPS, that acts primarily on B lymphocytes, *via*B Cell Receptor and Toll-like 4 Receptor. AEGH inhibited lymphoproliferation induced by both mitogens in 23.56% and 31.77%, respectively (P \< 0.05) (Fig. **[2B](#F2){ref-type="fig"}**, **[C](#F2){ref-type="fig"}**).

Inaddition, AEGH showed no cytotoxicity on lymphocytes (Fig. **[2A](#F2){ref-type="fig"}**) at the treatment doses, maintaining cells viability similar to the unexposed control cells.

DISCUSSION
==========

In order to evaluate the effect of AEGH on inflammation we chose an arthritis immunomediated T cell-dependent model. This model produces an acute inflammation and similar pathological aspects of RA \[[@R15]\]. In this model, the i.a. injection of mBSA induces accentuated migration of leucocytes after 6 h, with a highest influx on 24 h \[[@R16]\]. Additionally, the inflammatory process with cell influx and circulation of proinflammatory cytokines such as interleukin (IL)-6, IL-1β, IL-2 and interferon γ generate accentuated nociception.

In our study, treatment with AEGH markedly reduced nociception induced by AIA. This finding corroborates with the study of *Do Monte et. al*. (2004) \[[@R14]\], where treatments with hydroalcoholic extract of *E. arvense*reduced nociception in mouse experimental models of abdominal constriction and formalin-injected paw. Also, leukocytes migration locally was reduced with treatment. This finding confirms again the study of *Do Monte et al. (2004)* \[[@R14]\], where treatment with hydroalcoholic extract of *E. arvense*reduced mice paw edema caused by injection of carrageenan.

Regarding the pharmacological activity, previous studies have shown that *Equisetum* species presents antioxidant, antinociceptive and anti-inflammatory activities \[[@R12],[@R14]\], however this is the first study to evaluate the anti-inflammatory effect of this specie (*E. giganteum*) on a model of arthritis and on lymphocytes *in vitro*. Our results agree with the previously reported anti-inflammatory and antinociceptive effects of flavonoids \[[@R19]\], the major secondary metabolites present in *E. giganteum* \[[@R9]\]. One of the important mechanisms of flavonoids in these processes can be an inhibition of eicosanoid generating enzymes including phospholipase A2, cyclooxygenases, and lipoxygenases, thereby reducing the concentrations of prostanoids and leukotrienes \[[@R20]\]. For other compounds, such as styrylpyrones and hydroxycinnamic acid derivatives, antioxidant \[[@R21],[@R22]\] and NF-κB inhibitory activity \[[@R23],[@R24]\] have been reported.

In conclusion, our study shows that AEGH has an interesting anti-inflammatory potential in an acute model of inflammation, as well as immunomodulatory effect on both B and T lymphocytes, with an action independent of cytotoxicity. Further studies are needed to better explore the immuno-inflammatory pathways affected by AEGH, as well as its potential clinical use.
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![In vivo experiments. (A) Nociception, evaluated at 0, 1, 3, 6 and 24 hours after i.a. injection. Each bars represents mean ± SEM (n= 7). \*P \< 0.05 on time 1, \*\*P \< 0.01 on times 3, 6 and 24 h versus vehicle treatment, by two-way analysis of variance (ANOVA) followed by the Tukey's post hoc test. (B). Leucocyte migration into the articular cavity of the knee joint, assessed 48 hours after treatment with vehicle or AEGH \[600 mg/kg orally, twice a day\]. Injection of saline alone was used as negative control. Each bar represents mean ± SEM (n= 7). \*P = 0.015 versus vehicle treatment, by Student's unpaired t-test.](TORJ-7-129_F1){#F1}

![In vitro assay. (A) Effect of AEGH on lymphocyte cell viability. Lymphocytes were incubated with AEGH at indicated concentrations for 48 h. Each bar represents mean ± SEM. Treatment with AEGH did not affect cell viability. (B) Effect of AEGH on lymphocyte proliferation induced by ConA \[5 μg/ml\] and treated with or without AEGH \[80 μg/ml\] for 48 h. Each bar represents mean ± SEM (n=6). Cells incubated only with RPMI medium were used as unstimulated controls. \*P \< 0.05 versus ConA stimulated but non-treated cells, by Student's unpaired t-test. (C). Effect of AEGH on lymphocyte proliferation induced by LPS. Lymphocytes were incubated with LPS \[10 μg/ml\] and treated with or without AEGH \[80 μg/ml\] for 48 h. Each bars represents mean ± SEM (n=6). Cells incubated only with RPMI medium was used as unstimulated control. \*P \< 0.05 versus LPS stimulated but nontreated cells, by Student's unpaired t-test.](TORJ-7-129_F2){#F2}
